Low levels of neutralizing antibodies against SARS-CoV-2 KP.3.1.1 and XEC in serum from seniors in May 2024
Even FossumiD, Elisabeth Lea VikseiD, Anna Hayman RobertsoniD, Asia‐Sophia WolfiD, Andreas RohringeriD, Lill TrogstadiD, Siri MjaalandiD, Olav HungnesiD, Karoline BragstadiD
Abstract
New immune evasive variants of SARS-CoV-2 may increase infections and hospitalizations in risk groups, such as the elderly. In this study we evaluated neutralizing antibodies against KP.3.1.1 and XEC, virus variants that are either widely distributed or on the rise globally, in sera from a cohort of seniors aged 68 - 82 years from April/May 2024. Neutralizing responses were low against both KP.3.1.1 and XEC, supporting the recommendation of an updated covid-19 vaccine booster in this age group.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 5
- FWCI
- 3.34
- Field percentile
- top 8%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mitigation of imprinted antibody responses in elderly COVID-19 highly vaccinated individuals
Rebecca B. Morse, Daniel J.S. Egan, … Ravindra K. Gupta·Journal of InfectionPeer-reviewed·Oct 1, 2026
- Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC
Prerna Arora, Christine Happle, … Markus Hoffmann·The Lancet Infectious DiseasesPeer-reviewed·Nov 7, 2024
- Competent immune responses to SARS-CoV-2 variants in older adults following mRNA vaccination
M. Jergovic, J. L. Uhrlaub, … J. Nikolich-Zugich·bioRxiv·Jul 22, 2021
- SARS-CoV-2 BA.3.2.2 is more evasive of neutralization by sera from young children
Madeline Wu, Hsiang Hong, … Ian A. Mellis·bioRxiv·Jun 3, 2026
- Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster
U. Marking, O. Bladh, … C. Thalin·bioRxiv·Dec 21, 2023
- KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2
Qian Wang, Ian A. Mellis, … David D. Ho·The Lancet Infectious DiseasesPeer-reviewed·Feb 4, 2025